Home Program Manager
Outset MedicalSalary not specified
- Full Time
- Junior (1 to 2 years)
About Outset Medical
Outset Medical focuses on improving dialysis treatment in the healthcare sector. Their main product, Tablo, is a system that simplifies the dialysis process by integrating with electronic medical record (EMR) platforms, allowing for better management of patient data with real-time updates and alerts. This helps streamline workflows from charting to billing. In addition to Tablo, Outset Medical provides educational programs and hands-on training for dialysis professionals, including a Vascular Access Program that enhances staff skills in cannulation and vascular access management. They also offer a Bridge Program to assist facilities transitioning to in-house dialysis services by providing experienced dialysis nurses for training and support. Outset Medical aims to enhance the quality of care for dialysis patients across various settings, including hospitals, outpatient clinics, and home care.
San Jose, CaliforniaHeadquarters
2010Year Founded
$542.8MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
501-1,000Employees
Benefits
Medical, dental, & vision
Life Insurance/AD&D
FSA & HSA
401k
Parental leave
Pet insurance
Tuition reimbursement
PTO
Company events
Risks
Multiple class action lawsuits could lead to financial and reputational damage for Outset.
The shipment pause of TabloCart with Prefiltration may have disrupted supply chains.
Reliance on partnerships, like with U.S. Renal Care, poses risks if expectations aren't met.
Differentiation
Outset Medical's Tablo system integrates with EMR platforms for streamlined dialysis workflows.
The company offers a Vascular Access Program to enhance staff expertise in cannulation.
Outset Medical provides a Bridge Program for facilities transitioning to in-house dialysis services.
Upsides
Increased adoption of home dialysis solutions aligns with Outset's partnership with U.S. Renal Care.
The demand for portable dialysis machines supports the market potential for Outset's Tablo system.
Outset's FIPS 140-3 validation enhances cybersecurity, aligning with new medical device standards.
Funding
Total raised$542.78 M
Latest valuation$625.00 M
StageIPO
PRIVATE PLACEMENT VC
12/31/2024$169
POST IPO EQUITY
7/31/2023N/A
POST IPO DEBT
10/31/2022$300
IPO
8/31/2020$241
$125
$625.00 MSERIES D
7/31/2018$132
$660.00 MDEBT
6/30/2017$4
SERIES C
4/30/2017$76
$382.50 M$51
$255.00 MEARLY VC
1/31/2010$4
$22.50 M